Official Title
Safety and Efficacy of Baricitinib for COVID-19
Brief Summary

This study plans to learn more about the effects of a medicine called baricitinib on the progression of COVID-19 (coronavirus disease of 2019), the medical condition caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Baricitinib is FDA-approved for the treatment of rheumatoid arthritis, an autoimmune condition. This study intends to define the impact of baricitinib on the severity and progression of COVID-19. This drug might to lower the hyperinflammation caused by the virus, which would prevent damage to the lungs and possibly other organs. The study will recruit patients who have been diagnosed with COVID-19. The goal is to recruit 80 patients.

Detailed Description

This is an adaptive Phase 2/3 clinical trial, with a focus on the assessment of safety in the

first 20 participants (Phase 2), followed by a much broader assessment of efficacy, while

continuing to monitor safety, in an additional 60 participants (Phase 3, total participants

across Phase 2/3 n=80). Both phases are single arm, open label, and occur at a single site at

the University of Colorado Hospital (UCH). Data from participants in this study will be

compared with data from other COVID-19 patients not receiving baricitinib. Study participants

will receive 2 mg/day of baricitinib for 14 days and will be followed for up to 29 days.

Not yet recruiting
COVID-19

Drug: Baricitinib
Subjects will receive a 2 mg oral dose of baricitinib.
Baricitinib Arm

Eligibility Criteria

Inclusion Criteria: - Male or female aged 18 - 89 years at time of enrollment - Hospitalized (or documented plan to hospitalize if patient is in the emergency department) with symptoms suggestive of COVID-19 - Illness of any duration that meets each of the following: 1. Evidence of pneumonia, including radiographic infiltrates by imaging (chest x-ray, CT scan, etc.) or clinical assessment (rales/crackles on exam) 2. Requires supportive care, including non-invasive supplemental oxygen - Laboratory-confirmed SARS-CoV-2 infection as determined by PCR or other commercial or public health assay within 7 days of enrollment - Understands and agrees to comply with planned study procedures - Provides informed consent signed by study patient or legally acceptable representative

Exclusion Criteria: - Absolute lymphocyte count is less than 500 cells/mm - Absolute neutrophil count is less than 1000 cells/mm - Hemoglobin level is less than 8 g/dL - Estimated GFR is less than 60 mL/min/1.73 m2 - ALT or AST is over 5 times the upper limit of normal - Treatment with other JAK inhibitors, OAT3 inhibitors, biologic disease-modifying anti-rheumatic drugs (DMARDs), anti-IL-6 or anti-IL-6R antibodies, or potent immunosuppressants such as azathioprine. and cyclosporine concurrently or within the past 5 days. Note: recent or concurrent treatment with hydroxychloroquine or chloroquine is allowable, as these are 'non-biologic' DMARDs with potential antiviral activity. - History of HIV infection and on active immunosuppressant therapy - Current hematological or solid organ malignancy and on active immunosuppressant therapy - Active tuberculosis (TB) infection or known or suspected systemic bacterial or fungal infection - Pregnancy or breast feeding - Known allergy to baricitinib - In the opinion of the investigator, they are unlikely to survive for >48 hours from screening - Any physical examination findings and/or history of any illness that, in the opinion of the investigator, might confound the results of the study or pose an additional risk to the patient by their participation in the study

Additional Exclusion Criteria for Phase 2 only:

• Invasive oxygen supplementation, including mechanical ventilation and extracorporeal
membrane oxygenation (ECMO)

Eligibility Gender
All
Eligibility Age
Minimum: 18 Years~Maximum: 89 Years
Countries
United States
Locations

University of Colorado, Denver
Aurora, Colorado, 80045

Contacts

Angela Rachubinski, PhD
(720) 507-9107
bari-covid19@cuanschutz.edu

Joaquin Espinosa, PhD
(720) 507-9107
bari-covid19@cuanschutz.edu

Joaquin Espinosa, PhD
Principal Investigator
University of Colorado, Denver

University of Colorado, Denver
NCT Number
Keywords
JAK inhibitor
SARS-CoV-2
inflammation
cytokine release syndrome